SAFETY DATA SHEETS

This SDS packet was issued with item: 078363023

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078056502 078363049 078739052 078739078 078938798 078938805 078938809

The safety data sheets (SDS) in this packet apply to one or more components included in the items listed below. Items listed below may require one or more SDS. Please refer to invoice for specific item number(s).

078363031



MSD Animal Health Wim de Körverstraat 35 5831 AN Boxmeer Netherlands

SAFETY DATA SHEET

MSD Animal Health urges each user or recipient of this SDS to read the entire data sheet to become aware of the hazards associated with this material.

SECTION 1. IDENTIFICATION OF SUBSTANCE AND CONTACT INFORMATION

SDS NAME:	PANACUR granules
SYNONYM(S):	PANACUR granules PANACUR granules 1lb jar PANACUR granules 1g packet PANACUR granules 2g packet PANACUR granules 4g packet PANACUR C granules 1 g packet PANACUR C granules 2g packet PANACUR C granules 2g packet
SDS Number:	SP002199
EMERGENCY NUMBER(S):	+1 (908) 423-6000 (24/7/365) English Only
	EU Transportation Emergencies - Carechem24: +44 (0)208 762 8322 (24 hours/7 days/week)
INFORMATION:	+31 (0) 485-587600 (MSD Animal Health - Boxmeer, Netherlands)
MERCK SDS HELPLINE:	+1 (908) 473-3371 (Worldwide) Monday to Friday, 9am to 5pm (US Eastern Time)
SDS EMAIL:	spmsds@spcorp.com
The brand-names or trademarks indicated b	by CAPITAL LETTERS in this [MISDS are the property of licensed to promoted or distributed by Merck 8

The brand-names or trademarks indicated by CAPITAL LETTERS in this [M]SDS are the property of, licensed to, promoted or distributed by Merck & Co., Inc., its subsidiaries or related companies.

EU CLASSIFICATION(S):

Repr.Cat.3;R63 N;R50/53

EMERGENCY OVERVIEW

White to off-white Granules Odor unknown May be irritating to skin and eyes. May cause skin sensitization in sensitive individuals. May cause effects to: liver kidney gastrointestinal tract stomach immune system blood central nervous system fetus Very toxic to aquatic organisms. May cause long-term adverse effects in the aquatic environment.

POTENTIAL HEALTH EFFECTS:

The information presented below pertains to the following individual ingredients, and not to the mixture(s). Only information about the ingredients that are expected to contribute significantly to the potential health hazard profile of the formulation(s) are presented.

The active ingredient fenbendazole is a benzimidazole carbamate anthelmintic that is structurally related to mebendazole. Therapeutic use of mebendazole, a substance of the same chemical class as fenbendazole, has been reported to cause gastrointestinal disturbances (transient abdominal pain), diarrhea, headache, and dizziness. Frequent effects reported after treatment with high-doses of mebendazole have included allergic reactions (fever and skin reactions), raised liver enzyme values, alopecia, bone marrow depression, reduced leucocyte count and raised serum-transaminase values.

A number of oral subchronic and chronic animal studies have been conducted with fenbendazole and have demonstrated that the liver is the main target tissue. In addition, stomach, kidneys, blood, immune system, and central nervous system are also affected by treatment with fenbendazole. Devlopmental effects have been reported in rabbits following treatment with fenbendazole.

LISTED CARCINOGENS

No carcinogens or potential carcinogens listed by IARC or EU Directive 90/394 (Annex I) in this mixture.

SECTION 3. COMPOSITION AND INFORMATION ON INGREDIENTS

PRODUCT USE: Veterinary product

CHEMICAL FORMULA: Mixture.

The formulation for this product is proprietary information. Only hazardous ingredients in concentrations of 1% or greater and/or carcinogenic ingredients in concentrations of 0.1% or greater are listed in the Chemical Composition table. Active ingredients in any concentration are listed. For additional information about carcinogenic ingredients see Section 2.

This formulation may contain some sodium hydroxide for pH adjustment.

CHEMICAL COMPOSITION

INGREDIENT	CAS NUMBER	EC NUMBER	EU CLASSIFICATION	PERCENT
Fenbendazole	43210-67-9	256-145-7	Repr. Cat.3;R63	10-22.2%
			N;R50-53	

Fields in the above table that do not contain data indicate that the substance(s) have not been listed or classified according to EU criteria.

ADDITIONAL INFORMATION: This MSDS is written to provide health and safety information for individuals who will be handling the final product formulation during research, manufacturing, and distribution. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate MSDS for each ingredient. Refer to the package insert or product label for handling guidance for the consumer.

SDS NAME: PANACUR granules

Latest Revision Date: 13-Oct-2011

Page 2 of 8

SDS Number: SP002199

Published Date: 13-Jan-2011

SECTION 4. FIRST AID MEASURES
Remove to fresh air. If any trouble breathing, get immediate medical attention. Administer artificial respiration if breathing has ceased. If irritation or symptoms occur or persist, consult a physician.
In case of skin contact, while wearing protective gloves, carefully remove any contaminated clothing, including shoes, and wash skin thoroughly with soap and water. If irritation or symptoms occur or persist, consult a physician.
In case of eye contact, immediately rinse eyes thoroughly with plenty of water. If wearing contact lenses, remove only after initial rinse, and continue rinsing eyes for at least 15 minutes. If irritation occurs or persists, consult a physician.
Rinse mouth and drink a glass of water. Do not induce vomiting unless under the direction of a qualified medical professional or Poison Control Center. If symptoms persist, consult a physician.

SECTION 5. FIRE FIGHTING MEASURES

FLAMMABILITY DATA:

Flash Point:

Not determined (liquids) or not applicable (solids).

EXPLOSION HAZARDS:

Under normal conditions of use, this material does not present a significant fire or explosion hazard. However, like most organic compounds, this material may present a dust deflagration hazard if sufficient quantities are suspended in air. This hazard may exist where sufficient quantities of finely divided material are (or may become) suspended in air during typical process operations. An assessment of each operation should be conducted and suitable deflagration prevention and protection techniques employed. This material has been shown by standard laboratory testing to exhibit a low sensitivity to ignition by electrostatic discharges. However, all large conductive items used during processing of this material should be suitably grounded.

SPECIAL FIRE FIGHTING PROCEDURES:

Wear full protective clothing and self-contained breathing apparatus (SCBA).

SUITABLE EXTINGUISHING MEDIA:

Carbon dioxide (CO2), extinguishing powder or water spray.

See Section 9 for Physical and Chemical Properties.

SECTION 6. ACCIDENTAL RELEASE MEASURES

PERSONAL PRECAUTIONS:

Wear appropriate personal protective equipment as specified in Section 8. Keep personnel away from the clean-up area.

SPILL RESPONSE / CLEANUP:

All spills should be handled according to site requirements and based on precautions cited in the MSDS. In the case of liquids, use proper absorbent materials. For laboratories and small-scale operations, incidental spills within a hood or enclosure should be cleaned by using a HEPA filtered vacuum or wet cleaning methods as appropriate. For large dry or liquid spills or those spills outside enclosure or hood, appropriate emergency response personnel should be notified. In manufacturing and large-scale operations, HEPA vacuuming prior to wet mopping or cleaning is required.

See Sections 9 and 10 for additional physical, chemical, and hazard information.

SECTION 7. HANDLING AND STORAGE

PRECAUTIONS FOR SAFE HANDLING

SDS NAME: PANACUR granules Latest Revision Date: 13-Oct-2011

Page 3 of 8

HANDLING:

Keep containers adequately sealed during material transfer, transport, or when not in use. Wash face, hands, and any exposed skin after handling. Do not eat, drink, or smoke when using this substance or mixture.

Appropriate handling of this material is dependent on many factors, including physical form, duration and frequency of process or task, and effectiveness of engineering controls. Site-specific risk assessments should be conducted to determine the feasibility and the appropriateness of all exposure control measures. See Section 8 (Exposure Controls) for additional guidance.

CONDITIONS FOR SAFE STORAGE, INCLUDING ANY IMCOMPATIBILITIES

STORAGE:

Store below 25 deg C. Store in adequately sealed container.

SPECIFIC END USE(S)

Refer to Section 1 for identified use(s).

See Section 8 for exposure controls and additional safe handling information.

SECTION 8. EXPOSURE CONTROLS AND PERSONAL PROTECTION

OCCUPATIONAL EXPOSURE GUIDELINE (OEG):

An Occupational Exposure Guideline (OEG) of 100 mcg/m3 (8-hr. TWA) has been established for fenbendazole.

EXPOSURE CONTROLS

The health hazard risks of handling this material are dependent on many factors, including physical form, duration and frequency of process or task, and effectiveness of engineering controls. Site-specific risk assessments should be conducted to determine the feasibility and the appropriateness of all exposure control measures. Exposure controls for normal operating or routine procedures follow a tiered strategy. Engineering controls are the preferred means of long-term or permanent exposure control. If engineering controls are not feasible, appropriate use of personal protective equipment (PPE) may be considered as alternative control measures. Exposure controls for non-routine operations must be evaluated and addressed as part of the site-specific risk assessment.

RECOMMENDED PERSONAL PROTECTIVE EQUIPMENT (PPE):

Respiratory Protection:	Respiratory protective equipment (RPE) may be required for certain laboratory and large-scale manufacturing tasks if potential airborne breathing zone concentrations of substances exceed the relevant exposure limit(s). Workplace risk assessment should be completed before specifying and implementing RPE usage. Potential exposure points and pathways, task duration and frequency, potential employee contact with the substance, and the ability of the substance to be rendered airborne during specific tasks should be evaluated. Initial and ongoing strategies of quantitative exposure measurement should be obtained as required by the workplace risk assessment. All RPE must conform to local and regional specifications for efficacy and performance. Consult your site or corporate health and safety professional for additional guidance.
Skin Protection:	Gloves that provide an appropriate barrier to the skin are recommended if there is potential for contact with this material. Consult your site safety staff for guidance.
Eye Protection:	Safety glasses with side shields. Use of goggles or full face protection may be required based on hazard, potential for contact, or level of exposure. Consult your site safety staff for guidance.
Body Protection:	In small-scale or laboratory operations, lab coats or equivalent protection is required. Disposable Tyvek or other dust impermeable suit should be considered based on procedure or level of exposure. Use of additional PPE such as shoe coverings, gauntlets, hood, or head covering may be necessary. Consult your site safety staff for guidance.
	In large-scale or manufacturing operations, disposable Tyvek or other dust impermeable suit is recommended and based on level of exposure. Use of additional PPE such as shoe coverings, gauntlets, hood, or head covering may be necessary. Consult your site safety staff for guidance.

EXPOSURE LIMIT VALUES:

Fields in the above table(s) that do not contain data indicate that exposure limits are not available for those endpoints.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

FORM:

Granules

SDS NAME: PANACUR granules Latest Revision Date: 13-Oct-2011

Page 4 of 8

SECTION 9.	PHYSICAL	AND CHEMICAL	PROPERTIES
------------	----------	--------------	-------------------

COLOR: ODOR: pH: SOLUBILITY: Water:

White to off-white Odor unknown 5-7

Insoluble

See Section 5 for flammability/explosivity information.

SECTION 10. STABILITY AND REACTIVITY

STABILITY/ REACTIVITY:

Stable under conditions specified in Section 7 of this SDS. No hazardous reactions known.

CONDITIONS AND MATERIALS TO AVOID:

None known.

HAZARDOUS DECOMPOSITION PRODUCTS / REACTIONS:

Carbon oxides (COx).

SECTION 11. TOXICOLOGICAL INFORMATION

The information presented below pertains to the following individual ingredients, and not to the mixture(s). Only information about the ingredients that are expected to contribute significantly to the potential health hazard profile of the formulation(s) is presented.

ACUTE TOXICITY DATA

SKIN:

Fenbendazole was not irritating to the skin of rabbits.

EYE:

Fenbendazole was not irritating to the eyes of rabbits.

ORAL:

Fenbendazole: Oral LD50: > 10 g/kg (rat)

REPEAT DOSE TOXICITY DATA

SUBCHRONIC / CHRONIC TOXICITY:

A number of oral subchronic and chronic animal studies have been conducted with fenbendazole and have demonstrated that the liver is the main target tissue. In addition, stomach, kidneys, blood, immune system, and central nervous system are also affected by treatment with fenbendazole.

Data in some animal species indicate that the ability of T and B lymphocytes to proliferate in the secondary immune response may be suppressed during treatment with fenbendazole.

High oral dosages (500-3000 mg/kg/day) during 2-week dosing in rats caused reduced body weight gain, and severe renal and liver toxicity. Fenbendazole did not cause treatment-related effects when administered via stomach tube to immature rats at the rate of 0, 25, 250, and 2500 mg/kg b.w./day for 30 days. In a 90- day study, rats administered fenbendazole at 1600 to 2500 mg/kg /day showed tremors. No other treatment-related findings were reported.

Fenbendazole did not cause treatment-related effects in dogs administered oral dosages ranging from 50 to 250 mg/kg/day in a 6-day study, 20 to 125 mg/kg/day in a 90-day study, or 1 to 10 mg/kg/day in a 14-week study. At higher dosages, or in longer term studies, treatment-related effects were observed. Common effects observed in these additional studies include lymph follicle proliferation or nodules in the gastric mucosa. These effects were observed in dogs administered 250 mg/kg/day in a 30-day study, and in dogs given 8 to 20 mg/kg/day in one 6-month study and 20 to 125 mg/kg/day in another 6-month study. In addition to these effects, focal encephalomalacia, satellitosis, neuronophagia, perivascular inflammation or gliosis were observed in the cerebra of three dogs given 125 mg/kg/day for 6 months, and hyperplasia and congestion of the mesenteric lymph nodes were noted in dogs administered 8 to 20 mg/kg/day in the other 6-month study. [NOELS: 30-day Study: 25 mg/kg/day, 6-month Study (high-dose): none established, and 6-month Study (low-dose): 4 mg/kg/day]

REPRODUCTIVE / DEVELOPMENTAL TOXICITY:

Fenbendazole was found not to be teratogenic when tested in rats, dogs, or rabbits. Developmental effects (abortions, resorptions, and decreased fetal weights) were observed in the absence of maternal toxicity only in rabbits. When used in pigs, sheep, horses, and cattle, no relevant adverse effects on reproductive ability or offspring survival have been noted.

Fendbendazole was administered to rats at dietary dosages ranging from 5 to 135 mg/kg/day in a three-generation reproduction study. Reproductive and/or developmental effects observed in the 45 and 135 and 45 mg/kg/day dosage groups include reduced fertility indices, survival indices, pup weight, and pup growth, as well as diarrhea, yellow color, reduced activity, bloated stomach, and alopecia. These effects were more pronounced in the high-dose group. The NOEL for this study was 15 mg/kg/day for maternal and reproductive toxicity.

The potential embryotoxicity of fenbendazole was evaluated in pregnant rabbits, administered doses via stomach tube of 0, 10, 25, and 63 mg/kg/day on gestation days 7-19. Abortion or resorption of litters was observed in the 63 and 25 mg/kg/day dose groups. An increase in skeletal anomalies (13th rib) and delayed ossification of cranial bones also occurred in the high dose group. The NOEL for this study was 25 mg/kg/day.

Fenbendazole was administered to 2 groups of 12 female dogs at oral doses of 100 mg/kg/day, on gestation days 14-22 or 22-30. Developmental toxicity (stillborn pups and survival indices) were observed. About half the dogs in each group produced litters. No macroscopic abnormalities were observed in pups that died during the study.

MUTAGENICITY / GENOTOXICITY:

Fenbendazole was negative in a bacterial mutagenicity assay, a chromosomal aberration study, micronucleus, and DNA repair assay. It was weakly positive in the mouse lymphoma assay. Fenbendazole increased the mitotic index of HeLa cells in vitro, an effect that could be related to the ability of benzimidazoles to interfere with tubulin polymerization and thus inhibit spindle formation.

CARCINOGENICITY:

Fenbendazole was not carcinogenic in mice receiving 45 to 405 mg/kg fenbendazole in the diet for 2 years.

A two-year oral carcinogenicity study has been conducted in rats at dose levels of 0, 5, 15, 45, and 135 mg/kg/day. Treatment-related signs reported included diarrhea and red feces (45 mg/kg/day and 135 mg/kg/day) and reddish-brown urine (15, 45, and 135 mg/kg/day). Mortality was not statistically different from controls for any treatment group. Body weights and weight gains at study termination were significantly lower for the 45 and 135 mg/kg/day groups compared with controls. The alkaline phosphatase in all dose groups and SGOT in the high dose group were consistently elevated. Necropsy revealed enlargement or cyst formation in lymph nodes of rats in the two highest dose groups.liver mass and/or nodule formation, cyst formation in the liver of females, and testicular masses among males were reported at the 135 mg/kg/day dose-level.

Further treatment-related effects included sinus ectasia and hyperplasia of the mesenteric lymph nodes in all but the low dose group; Additionally, liver hypertrophy and hyperplasia, hepatocellular cytoplasmic vacuolation, bile duct proliferation, biliary cyst formation, and nodular hepatocellular hyperplasia were reported in female rats at the two highest dose levels. Testicular interstitial cell adenomas in the 135 mg/kg/day male rats were observed. The NOEL for this study was 5 mg/kg/day.

SECTION 12. ECOLOGICAL INFORMATION

There are no data for the final product or its formulation(s). The information presented below pertains to the following ingredient(s).

ECOTOXICITY DATA

INGREDIENT ECOTOXICITY

Fenbendazole: 96-hr LC50 (trout): 0.04 mg/L 48-hr LC50 (daphnia): 0.009-0.012 mg/L 96-hr LC50 (zebra fish): >500 mg/kg 21-day LC50 (bluegill sunfish): >0.019 mg/L 96-hr LC50 fish (Lepomis macrochirus): 1000 mg/L (highest concentration tested) 96-hr fish (Salmo gardneri): 7.5 mg/L (highest concentration tested) Earthworm toxicity (LC50): 180 mg/kg (28 days) Dung beetle toxicity (LD50): >770 mg/kg (7 days)

ENVIRONMENTAL DATA

OTHER INGREDIENT ENVIRONMENTAL DATA:

Fenbendazole: Partition Coefficient (log Pow): 3.3 Fenbendazole: Aerobic Biodegradation (soil) Results: DT50 between 4 and 12 days (for three types of soil) Fenbendazole: Not readily biodegradable.

SECTION 13. DISPOSAL CONSIDERATIONS

WASTE TREATMENT METHODS

SDS NAME: PANACUR granules Latest Revision Date: 13-Oct-2011

Page 6 of 8

MATERIAL WASTE:

Disposal must be in accordance with applicable federal, state/provincial, and/or local regulations. Incineration is the preferred method of disposal, when appropriate. Operations that involve the crushing or shredding of waste materials or returned goods must be handled to meet the recommended exposure limit(s).

PACKAGING AND CONTAINERS:

Disposal must be in accordance with applicable federal, state/provincial, and/or local regulations.

SECTION 14. TRANSPORT INFORMATION

Refer to site-specific procedures and requirements for additional guidance.

IATA/ICAO CLASSIFICATION:

This classification only applies in a transport chain to/from a country which regulates this material as an environmentally hazardous substance. For all other air shipments, this material is non-regulated.

Proper Shipping Name:	Environmentally hazardous substance, solid, n.o.s. (Fenbendazole)
Hazard Class:	9
UN Number:	UN 3077
Packing Group:	III

ADR CLASSIFICATION:

ADR Special Provision 601 exempts pharmaceutical products which are also environmentally hazardous substances from all ADR regulation.

Per ADR special provision 601, as a pharmaceutical product (medicine) ready for use, this material is not regulated as a dangerous good for transport within Europe.

Proper Shipping Name:	Environmentally hazardous substance, solid, n.o.s. (Fenbendazole)
Hazard Class:	9
UN Number:	UN 3077
Packing Group:	III
Classification Code:	M7

IMDG/IMO CLASSIFICATION:

Proper Shipping Name:	Environmentally hazardous substance, solid, n.o.s. (Fenbendazole)
Hazard Class:	9
UN Number:	UN 3077
Packing Group:	III

SECTION 15. REGULATORY INFORMATION

The following classification is based on available data and is in accordance with European Union criteria.

EUROPEAN UNION REGULATIONS:

The classification presented below is based on the active ingredient(s) and individual hazardous ingredients in the product formulation.

Indication of Danger:

Xn - Harmful. N - Dangerous For The Environment.



Risk Phrases:

R63 - Possible risk of harm to the unborn child.

R50/53 - Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

Safety Phrases:

S29 - Do not empty into drains.

S46 - If swallowed, seek medical advice immediately and show this container or label.

S61 - Avoid release to the environment. Refer to special instructions/Safety data sheets.

S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.

S 1/2 - Keep locked-up and out of the reach of children.

S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection.

S24/25 - Avoid contact with skin and eyes.

SDS NAME: PANACUR granules

Latest Revision Date: 13-Oct-2011

Page 7 of 8

SECTION 16. OTHER INFORMATION

Although reasonable care has been taken in the preparation of this document, we extend no warranties and make no representations as to the accuracy or completeness of the information contained therein, and assume no responsibility regarding the suitability of this information for the user's intended purposes or for the consequence of its use. Each individual should make a determination as to the suitability of the information for their particular purpose(s).

The brand-names or trademarks indicated by CAPITAL LETTERS in this [M]SDS are the property of, licensed to, promoted or distributed by Merck & Co., Inc., its subsidiaries or related companies.

 DEPARTMENT ISSUING MSDS:
 Global Safety & the Environment
Merck & Co., Inc.
One Merck Drive
Whitehouse Station, NJ 08889

 MERCK SDS HELPLINE:
 +1 (908) 473-3371 (Worldwide)
Monday to Friday, 9am to 5pm (US Eastern Time)

 MSDS CREATION DATE:
SUPERSEDES DATE:
 13-Jan-2011
13-Jan-2011

 SIGNIFICANT CHANGES (EU SUBFORMAT):
 OEB

SDS NAME: PANACUR granules Latest Revision Date: 13-Oct-2011



Version 4.10	Revision Date: 08/16/2022		DS Number: 69753-00014	Date of last issue: 07/26/2022 Date of first issue: 02/27/2018		
SECTIO	ON 1. IDENTIFICATION					
Pro	oduct name	:	Fenbendazole (22	2.2%) Solid Formulation		
Ма	anufacturer or supplier's	deta	ails			
	mpany name of supplier dress	:	 Merck & Co., Inc 126 E. Lincoln Avenue Rahway, New Jersey U.S.A. 07065 			
	lephone	:	908-740-4000			
	nergency telephone mail address	:	1-908-423-6000 EHSDATASTEW	ARD@merck.com		
Re	commended use of the c	hen	nical and restriction	ons on use		
Re	commended use	:	Veterinary produc	t		
Re	strictions on use	:	Not applicable			
19	IS classification in accor 10.1200) mbustible dust	dan	ce with the OSHA	Hazard Communication Standard (29 CFR		
Re	productive toxicity	:	Category 2			
	ecific target organ toxicity epeated exposure (Oral)	:	Category 2 (Liver	, Stomach, Nervous system, Lymph nodes)		
GF	IS label elements					
Ha	zard pictograms	:				
Sig	gnal Word	:	Warning			
На	zard Statements	:	If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air. H361fd Suspected of damaging fertility. Suspected of damaging			

H361fd Suspected of damaging fertility. Suspected of damaging the unborn child.
H373 May cause damage to organs (Liver, Stomach, Nervous system, Lymph nodes) through prolonged or repeated exposure if swallowed.

Precautionary Statements : Prevention: P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe dust, fume, gas, mist, vapors or spray. P280 Wear protective gloves, protective clothing, eye protection and face protection.



Version	Revision Date:	SDS Number:	Date of last issue: 07/26/2022
4.10	08/16/2022	2569753-00014	Date of first issue: 02/27/2018

Response:

P308 + P313 IF exposed or concerned: Get medical attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Starch	9005-25-8	>= 50 - < 70
fenbendazole	43210-67-9	>= 20 - < 30
Actual concentration is withheld as a trade secret		

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	Suspected of damaging fertility. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure if swallowed. Contact with dust can cause mechanical irritation or drying of
Protection of first-aiders	:	the skin. Dust contact with the eyes can lead to mechanical irritation. First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment





Versio 4.10	on	Revision Date: 08/16/2022		9S Number: 69753-00014	Date of last issue: 07/26/2022 Date of first issue: 02/27/2018
١	Notes to	o physician	:		l for exposure exists (see section 8). cally and supportively.
SECT	FION 5.	FIRE-FIGHTING MEA	ASU	IRES	
ę	Suitable	e extinguishing media	:	Water spray Alcohol-resistant f Carbon dioxide (C Dry chemical	
	Unsuita media	ble extinguishing	:	None known.	
	Specific fighting	c hazards during fire	:	Exposure to comb	ustion products may be a hazard to health.
ŀ		ous combustion prod-	:	Carbon oxides Nitrogen oxides (N Sulfur oxides	NOx)
	Specific ods	extinguishing meth-	:	cumstances and t Use water spray to Remove undamag so.	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do
		protective equipment fighters	:	Evacuate area. In the event of fire Use personal prot	, wear self-contained breathing apparatus. ective equipment.
SECT	FION 6.	ACCIDENTAL RELE	ASI	EMEASURES	
t	tive equ	al precautions, protec- upment and emer- procedures	:		ective equipment. ng advice (see section 7) and personal ent recommendations (see section 8).
E	Environ	mental precautions	:	Retain and dispos	akage or spillage if safe to do so. e of contaminated wash water. hould be advised if significant spillages
		s and materials for ment and cleaning up	:	container for disper Avoid dispersal of with compressed Dust deposits sho surfaces, as these released into the a Local or national r disposal of this ma employed in the c determine which r Sections 13 and 1	dust in the air (i.e., clearing dust surfaces

SECTION 7. HANDLING AND STORAGE

Technical measures

: Static electricity may accumulate and ignite suspended dust



Version 4.10	Revision Date: 08/16/2022	SDS Nun 2569753-		Date of last issue: 07/26/2022 Date of first issue: 02/27/2018
	Fotal ventilation on safe handling	Provid and b : Use o : Do no Do no Avoid Avoid Handl practi asses Minim Keep Keep Take Take	onding, or ir nly with ade t breathe du t swallow. contact with prolonged of e in accorda ce, based o sment ize dust gen container cl away from I precautiona	precautions, such as electrical grounding nert atmospheres. equate ventilation. ust, fume, gas, mist, vapors or spray.
Conditi	ions for safe storage	Store	locked up.	abeled containers.
Materia	als to avoid	: Do no		ce with the particular national regulations. the following product types: agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Starch	9005-25-8	TWA	10 mg/m³	ACGIH
		TWA (Res- pirable)	5 mg/m³	NIOSH REL
		TWA (total)	10 mg/m³	NIOSH REL
		TWA (total dust)	15 mg/m³	OSHA Z-1
		TWA (respir- able fraction)	5 mg/m³	OSHA Z-1
fenbendazole	43210-67-9	TWA	100 µg/m3 (OEB 2)	Internal

Engineering measures

Use feasible engineering controls to minimize exposure to compound.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided



Version 4.10	Revision Date: 08/16/2022	SDS Number: 2569753-00014	Date of last issue: 07/26/2022 Date of first issue: 02/27/2018
		hazardous che supplied respir release, expos	respirators against exposure to any mical is limited. Use a positive pressure air ator if there is any potential for uncontrolled ure levels are unknown, or any other where air purifying respirators may not provide ection.
	protection aterial	· Chomical rosis	tant glovos
IVIC	alena	: Chemical-resis	tant gloves
Eye p	rotection	If the work envi mists or aeroso Wear a faceshi	asses with side shields or goggles. ironment or activity involves dusty conditions, ols, wear the appropriate goggles. ield or other full face protection if there is a rect contact to the face with dusts, mists, or
	and body protection ne measures	: If exposure to or eye flushing sy working place. When using do Wash contamin The effective or engineering co appropriate deg	or laboratory coat. chemical is likely during typical use, provide stems and safety showers close to the not eat, drink or smoke. nated clothing before re-use. peration of a facility should include review of ntrols, proper personal protective equipment, gowning and decontamination procedures, ene monitoring, medical surveillance and the trative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	granules
Color	:	white to off-white
Odor	:	No data available
Odor Threshold	:	No data available
рН	:	5 - 7
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available

SAFETY DATA SHEET



Fenbendazole (22.2%) Solid Formulation

Vers 4.10		Revision Date: 08/16/2022		S Number: 9753-00014	Date of last issue: 07/26/2022 Date of first issue: 02/27/2018
		explosion limit / Lower bility limit	:	No data available	
	Vapor p	oressure	:	Not applicable	
	Relative	e vapor density	:	Not applicable	
	Relative	e density	:	No data available)
	Density	/	:	No data available	9
	Solubili Wat	ity(ies) er solubility	:	insoluble	
	Partitio octanol	n coefficient: n-	:	Not applicable	
		nition temperature	:	No data available)
	Decom	position temperature	:	No data available	9
	Viscosi Visc	ty cosity, kinematic	:	Not applicable	
	Explosi	ve properties	:	Not explosive	
	Oxidizii	ng properties	:	The substance of	r mixture is not classified as oxidizing.
	Molecu	lar weight	:	No data available	9
	Particle	e size	:	No data available	9

SECTION 10. STABILITY AND REACTIVITY

Reactivity Chemical stability Possibility of hazardous reac- tions	:	Not classified as a reactivity hazard. Stable under normal conditions. May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials		Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact



0	Revision Date: 08/16/2022	SDS Number: 2569753-00014	Date of last issue: 07/26/2022 Date of first issue: 02/27/2018
Acute	e toxicity		
	lassified based on av	ailable information.	
Com	ponents:		
Starc	:h:		
Acute	e oral toxicity	: LD50 (Rat): 3	> 5,000 mg/kg
Acute	e dermal toxicity	: LD50 (Rabbi	t): > 2,000 mg/kg
fenbe	endazole:		
Acute	e oral toxicity	: LD50 (Rat): >	> 10,000 mg/kg
		LD50 (Mouse	e): > 10,000 mg/kg
-	corrosion/irritation lassified based on av	ailable information	
	ponents:		
	endazole:		
Speci		: Rabbit	
Resu		: No skin irrita	tion
	ous eye damage/eye lassified based on av		
Not c	lassified based on av ponents: :h: ies		ion
Not c <u>Com</u> Starc Speci Resu	lassified based on av ponents: :h: ies	ailable information.	ion
Not c <u>Com</u> Starc Speci Resu	lassified based on av ponents: :h: ies It endazole: ies	ailable information.	
Not c <u>Com</u> Starc Speci Resu fenbe Speci Resu	lassified based on av ponents: :h: ies It endazole: ies	ailable information. : Rabbit : No eye irritat : Rabbit : No eye irritat	
Not c Com Starc Speci Resu fenbe Speci Resu Resu Skin	lassified based on av ponents: :h: ies It endazole: ies It	ailable information. : Rabbit : No eye irritat : Rabbit : No eye irritat itization	
Not c Com Starc Speci Resu fenbe Speci Resu Resu Resu Skin Not c	lassified based on av ponents: h: ies lt endazole: ies lt iratory or skin sens sensitization	ailable information. : Rabbit : No eye irritat : Rabbit : No eye irritat itization ailable information.	
Not c Com Starc Speci Resu fenbe Speci Resu Resu Resu Skin Not c Resp	lassified based on av ponents: h: ies lt endazole: ies lt iratory or skin sens sensitization lassified based on av	ailable information. : Rabbit : No eye irritat : Rabbit : No eye irritat itization ailable information.	
Not c Com Starc Speci Resu fenbe Speci Resu Resu Resp Not c	lassified based on av ponents: h: ies lt endazole: ies lt iratory or skin sens sensitization lassified based on av iratory sensitizatior	ailable information. : Rabbit : No eye irritat : Rabbit : No eye irritat itization ailable information.	





	Revision Date 08/16/2022		OS Number: 69753-00014	Date of last issue: 07/26/2022 Date of first issue: 02/27/2018
	cell mutagenici assified based or	•	information	
		available	imormation.	
Com	<u>oonents:</u>			
Starc	h:			
Geno	toxicity in vitro	:	Test Type: Bac Result: negative	terial reverse mutation assay (AMES) e
fenbe	endazole:			
Geno	toxicity in vitro	:	Test Type: Bac Result: negative	terial reverse mutation assay (AMES) e
			Test Type: DNA Result: negative	
			Test Type: Chro Result: negative	omosomal aberration
				ouse lymphoma cells ation: Metabolic activation
				-
	nogenicity lassified based or	n available	information.	
Not c		n available	information.	-
Not c <u>Com</u>	assified based or	n available	information.	
Not c Com fenbe Speci Applie	lassified based or <u>conents:</u> endazole: es cation Route sure time EL	n available : : : : :	information. Mouse oral (feed) 2 Years 405 mg/kg body negative	
Not c <u>Com</u> fenbe Speci Applic Expos NOAE Resu Speci Applic Expos NOAE Resu	lassified based or <u>conents:</u> endazole: es cation Route sure time EL it es cation Route sure time EL	n available	Mouse oral (feed) 2 Years 405 mg/kg body	/ weight /eight
Not c <u>Com</u> fenbe Speci Applic Expos NOAE Resu Speci Applic Expos NOAE Resu	assified based or <u>conents:</u> endazole: es cation Route sure time EL it es cation Route sure time EL it et Organs No ing	redient of t	Mouse oral (feed) 2 Years 405 mg/kg body negative Rat Oral 2 Years 5 mg/kg body w negative Lymph nodes, I	/ weight /eight _iver
Not c <u>Com</u> fenbe Speci Applic Expos NOAE Resu Speci Applic Expos NOAE Resu Targe	assified based or <u>conents:</u> endazole: es cation Route sure time EL it es cation Route sure time EL it es cation Route sure time EL it Mo ing identifi No cor	redient of t ed as prob	Mouse oral (feed) 2 Years 405 mg/kg body negative Rat Oral 2 Years 5 mg/kg body w negative Lymph nodes, I his product prese able, possible or	/ weight reight liver ent at levels greater than or equal to 0.1% confirmed human carcinogen by IARC. sent at levels greater than or equal to 0.19





/ersion I.10	Revision Date: 08/16/2022	-)S Number: 69753-00014	Date of last issue: 07/26/2022 Date of first issue: 02/27/2018
Suspe	oductive toxicity ected of damaging fert conents:	tility. S	suspected of dam	naging the unborn child.
	endazole: ts on fertility	:	Species: Rat Application Rou General Toxicity	y Parent: NOÁEL: 15 mg/kg body weight .: 45 mg/kg body weight
Effect	ts on fetal developmer	nt :	Result: Embryo	emale
			Species: Rabbit Application Rou	ite: Oral Toxicity: NOAEL: 25 mg/kg body weight
			Species: Rabbit Application Rou	
			Species: Rat Application Rou Developmental	oryo-fetal development ite: Oral Toxicity: NOAEL: 120 mg/kg body weight cts on fetal development.
Repro sessn	oductive toxicity - As- nent	:	fertility, based o	of adverse effects on sexual function and on animal experiments., Some evidence of on development, based on animal

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Liver, Stomach, Nervous system, Lymph nodes) through prolonged or repeated exposure if swallowed.

Components:

fenbendazole:

Routes of exposure	:	Ingestion
Target Organs	:	Liver, Stomach, Nervous system, Lymph nodes
Assessment	:	May cause damage to organs through prolonged or repeated



ersion I 0	Revision Date: 08/16/2022	SDS Number: 2569753-00014	Date of last issue: 07/26/2022 Date of first issue: 02/27/2018
		exposure.	
Repe	ated dose toxicity		
Comp	oonents:		
Starc	h:		
Speci NOAE		: Rat : >= 2,000 mg/kg	,
	cation Route	: Skin contact	3
Expos Metho	sure time od	: 28 Days : OECD Test Gu	ideline 410
fenbe	endazole:		
Speci		: Rat	
LOAE Applic	cation Route	: 500 mg/kg : Oral	
Expos	sure time	: 2 Weeks	
Targe	t Organs	: Kidney, Liver	
Speci		: Rat	
NOAE Applic	L cation Route	: > 2,500 mg/kg : Oral	
Expos	sure time	: 30 Days	
Rema	irks	: No significant a	dverse effects were reported
Speci		: Rat	
LOAE	:L cation Route	: 1,600 mg/kg : Oral	
Expos	sure time	: 90 Days	
Targe Symp	t Organs	: Central nervous : Tremors	s system
Symp	lonis	. Hemors	
Speci NOAE		: Dog	
LOAE		: 4 mg/kg : 8 mg/kg	
	sure time	: 6 Months	
Targe	et Organs	: Stomach, Nerv	ous system, Lymph nodes
-	ation toxicity		
	assified based on av ponents:	allable information.	
-	endazole:		
	piration toxicity class	sification	
Expe	rience with human	exposure	
<u>Comp</u>	oonents:		
fenbe	endazole:		
	tion	· Symptoms: Ra	pid respiration, Salivation, anorexia, Diarrh





Fenbendazole (22.2%) Solid Formulation

Version 4.10	Revision Date: 08/16/2022		0S Number: 69753-00014	Date of last issue: 07/26/2022 Date of first issue: 02/27/2018
SECTION	N 12. ECOLOGICAL INFO	DRI	IATION	
Eco	toxicity			
<u>Con</u>	nponents:			
fent	pendazole:			
Toxi	city to fish	:	LC50 (Lepomis n Exposure time: 2	nacrochirus (Bluegill sunfish)): 0.009 mg/l 1 d
	city to daphnia and other atic invertebrates	:	Exposure time: 4	nagna (Water flea)): 0.008 mg/l 8 h ïest Guideline 202
aqua	city to daphnia and other atic invertebrates (Chron- xicity)	:	Exposure time: 2	magna (Water flea)): 0.00113 mg/l 1 Days est Guideline 211
	sistence and degradabili data available	ity		
Bioa	accumulative potential			
<u>Con</u>	nponents:			
Part	bendazole: ition coefficient: n- nol/water	:	log Pow: 3.32	
Mob	oility in soil			
<u>Con</u>	nponents:			
Dist	bendazole: ribution among environ- tal compartments	:	log Koc: 3.8 - 4.7 Method: FDA 3.0	
	er adverse effects data available			
SECTIO	N 13. DISPOSAL CONSI	DEF	ATIONS	
Was	bosal methods ate from residues taminated packaging	:	Empty containers	ordance with local regulations. should be taken to an approved waste

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.



rsion 0	Revision Date: 08/16/2022	SDS Numbe 2569753-000	
UN number Proper shipping name			NMENTALLY HAZARDOUS SUBSTANCE, SOLID
		N.O.S. (fenbend	dazole)
Class		: 9	
Packir Labels	ng group S	: III : 9	
ΙΑΤΑ-	DGR		
UN/ID	No.	: UN 3077	
	r shipping name	(fenbend	nentally hazardous substance, solid, n.o.s. lazole)
Class		: 9	
	ng group	: !!!	
Labels		: Miscellar	neous
aircraf		: 956	
ger air		: 956	
Enviro	nmentally hazardous	: yes	
IMDG			
UN nu		: UN 3077	
Prope	r shipping name	N.O.S.	NMENTALLY HAZARDOUS SUBSTANCE, SOLIE
Class		(fenbend : 9	azole)
	ng group	: 9 : 111	
Labels		: 9	
EmS (: F-A, S-F	
	e pollutant	: yes	
	port in bulk according		of MARPOL 73/78 and the IBC Code
	stic regulation	supplied.	
49 CF	R		
	/NA number	: UN 3077	
	r shipping name		nentally hazardous substance, solid, n.o.s.
Class		: 9	
	ng group	:	
Labels		: CLASS 9	
ERG (: 171	
	e pollutant rks		endazole) oplies only to containers over 119 gallons or 450
Rema		ILCIS.	

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.





Version	Revision Date:	SDS Number:	Date of last issue: 07/26/2022
4.10	08/16/2022	2569753-00014	Date of first issue: 02/27/2018

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards	:	Combustible dust Reproductive toxicity Specific target organ toxicity (single or repeated exposure)
SARA 313	:	This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.
US State Regulations		

Pennsylvania Right To Know 9005-25-8 Starch D-Glucose, 4-O-β-D-galactopyranosyl-, monohydrate 64044-51-5 fenbendazole 43210-67-9 **California List of Hazardous Substances** Polyvinyl pyrrolidone 9003-39-8 **California Permissible Exposure Limits for Chemical Contaminants** 9005-25-8 Starch The ingredients of this product are reported in the following inventories: AICS : not determined DSL : not determined IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information





ACGIH	: USA. ACGIH Threshold Limit Values (TLV)	
NIOSH REL	: USA. NIOSH Recommended Exposure Limits	
OSHA Z-1	: USA. Occupational Exposure Limits (OSHA) - Table Z-1 Lin	n-
	its for Air Contaminants	
ACGIH / TWA	: 8-hour, time-weighted average	
NIOSH REL / TWA	: Time-weighted average concentration for up to a 10-hour	
	workday during a 40-hour workweek	
OSHA Z-1 / TWA	: 8-hour time weighted average	

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance: PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quanti-



Version	Revision Date:	SDS Number:	Date of last issue: 07/26/2022
4.10	08/16/2022	2569753-00014	Date of first issue: 02/27/2018

tative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to	:	Internal technical data, data from raw material SDSs, OECD
compile the Material Safety		eChem Portal search results and European Chemicals Agen-
Data Sheet		cy, http://echa.europa.eu/

Revision Date : 08/16/2022

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8